SLC5A2 and anemia: The cardiorenal protective mechanisms of SGLT2 inhibitors are thought to be complex, including diuretic effects that less activate the renin-angiotensin-aldosterone system with little change in intravascular volume (14, 15), suppression of sympathetic hyperactivity (16), antioxidant effects (17, 18), correction of impaired energy metabolism (19, 20), anti-inflammatory effects (21), improvement of anemia via increased erythropoietin production (22), improved iron metabolism (23), preventing fibrotic changes (24, 25), and preventing effects for the development of cardiorenal syndromes (26).